Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191029 | 0.89 | ROCK2 (0.57) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL12191087 | 0.89 | ROCK2 (0.57) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL27870261 | 0.86 | NPC1 (0.61) | NPC1ROCK2KMT2AALDH1A1LMNA | |
| SCHEMBL30573569 | 0.86 | NPC1 (0.61) | NPC1ROCK2KMT2AALDH1A1LMNA | |
| SCHEMBL12191092 | 0.86 | NPC1 (0.65) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL12191054 | 0.86 | NPC1 (0.65) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL12190909 | 0.85 | XDH (0.54) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL12191024 | 0.81 | HPGDS (0.49) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL13229283 | 0.80 | NPC1 (0.59) | NPC1ROCK2ROCK1KMT2AALDH1A1 | |
| SCHEMBL13325935 | 0.80 | NPC1 (0.59) | NPC1ROCK2ROCK1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | NADK, NAMPT, PDXK | GPR55 2285/4885NPC1 825/4885ROCK2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.